Hans-Georg Wirsching
Affiliations: | Department of Neurology | University Hospital Zurich, Zürich, Zürich, Switzerland |
Google:
"Hans-Georg Wirsching"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Eric Holland | research scientist | ||
| Michael Weller | research scientist | Neurology Department, University Hospital Zurich |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hertler C, Seystahl K, Le Rhun E, et al. (2022) Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology |
| Chen J, Sun S, Ren L, et al. (2021) mA Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes. Frontiers in Oncology. 11: 760892 |
| Maas SLN, Stichel D, Hielscher T, et al. (2021) Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100784 |
| Wirsching HG, Weller M, Balabanov S, et al. (2021) Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. Cancers. 13 |
| Wirsching HG, Steiner L, Becker D, et al. (2021) Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. Neuro-Oncology |
| Mastall M, Wolpert F, Gramatzki D, et al. (2021) Survival of brain tumour patients with epilepsy. Brain : a Journal of Neurology |
| Vils A, Bogowicz M, Tanadini-Lang S, et al. (2021) Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Frontiers in Oncology. 11: 636672 |
| Wirsching HG, Silginer M, Ventura E, et al. (2021) Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. Molecular Therapy Oncolytics. 20: 166-174 |
| Wirsching HG, Roth P, Weller M. (2021) A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion On Therapeutic Targets |
| Wirsching HG, Roelcke U, Weller J, et al. (2020) MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |